TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

TG Therapeutics, Inc.NASDAQ: TGTX

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue grows, but more slowly than its trailing trend

Q3 FY2026 cost of revenue of $42.08M rose 49.5% year over year, behind the +98.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at +624.3% a year.

Context

  • Cost of revenue amounted to 16.3% of revenue in FY2025, up 4.6 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +49.5% toward the trailing-twelve-month pace of +98.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$42.08M+2.1% QoQ
Last fiscal yearDec 2025
$100.71M+161.7% YoY
LTMSep 2026
$154.93M+98.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.5%——
1 year+161.7%——
3-year CAGR+624.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
100.71M USD
Year-over-year change
+161.7%
4-year CAGR
+236.0%

Cost of Revenue vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +98.5% is the highest of 6, against a peer median of -18.4%.
  • Cost of revenue amounts to 17.3% of revenue for TGTX, versus a peer median of 30.1%.
TGTX Competitors
Cost of Revenue for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$288M USD——7.0%
TGTXTG Therapeutics, Inc.LTM Sep 2026$154.93M USD+98.5%+624.3%17.3%
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
ADCTADC Therapeutics S.A.LTM Mar 2026$7.35M USD+33.7%+32.5%9.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K USD-99.5%—762.5%
ADAGAdagene Inc.LTM Jun 2024$425.46K USD——52.2%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$55K USD———
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding TGTX) —-18.4%+32.5%30.1%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.